Advertisement
YOU ARE HERE: LAT HomeCollectionsBenjamin Y Mahler
IN THE NEWS

Benjamin Y Mahler

FEATURED ARTICLES
BUSINESS
May 14, 1991 | GARY GORMAN, TIMES STAFF WRITER
Top executives of Amgen Inc., the Thousand Oaks-based biotechnology firm whose sales and stock price have skyrocketed since FDA approval of its two major drugs, were accused of insider stock trading in a lawsuit filed Monday in Ventura County Superior Court. The suit, filed by former Amgen contracts administrator Benjamin Y. Mahler, claims that former Amgen President Harry F. Hixson Jr.
ARTICLES BY DATE
BUSINESS
May 14, 1991 | GARY GORMAN, TIMES STAFF WRITER
Top executives of Amgen Inc., the Thousand Oaks-based biotechnology firm whose sales and stock price have skyrocketed since FDA approval of its two major drugs, were accused of insider stock trading in a lawsuit filed Monday in Ventura County Superior Court. The suit, filed by former Amgen contracts administrator Benjamin Y. Mahler, claims that former Amgen President Harry F. Hixson Jr.
Advertisement
BUSINESS
May 11, 1993
Ventura County Superior Court has dismissed an insider-trading lawsuit against former executives of Amgen Inc., the biotechnology firm based in Thousand Oaks. The suit was filed in June, 1991, by former Amgen contracts administrator Benjamin Y. Mahler, who accused former Amgen President Harry F. Hixson Jr. and two other company officials of publicly trading Amgen stock based on insider information related to when the federal Food and Drug Administration would approve Amgen's products.
CALIFORNIA | LOCAL
May 14, 1991 | GARY GORMAN, TIMES STAFF WRITER
Top executives of Amgen Inc., one of Ventura County's largest employers, were accused of insider stock trading in a lawsuit filed Monday in Ventura County Superior Court. The suit, filed by former Amgen contracts administrator Benjamin Y. Mahler, maintains that the company's former president, Harry F. Hixson Jr., and two current officials "publicly traded Amgen stock based on insider information as to when the FDA would approve" Amgen pharmaceuticals.
Los Angeles Times Articles
|